We searched for mutations in 22 cancer-related genes, using target sequencing techniques to further characterize the 12 patients who had AXL 3+ expression, of whom 6 had mutations in EGFR, 2 in KRAS, and 1 EML4–ALK fusion gene (Table 3). The gene discussed is KRAS; the disease is cancer.